Multiple sclerosis therapies (Syntonix Pharmaceuticals)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMultiple sclerosis therapies (Syntonix Pharmaceuticals)
Drug Alias Nameinterferon-beta:FcInterferon-β-Fc
ClassificationBiologics
Mechanisms of ActionInterferon beta stimulants
TargetsInterferon beta
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen Idec
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen (Denmark) A/S
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A